1
|
Zhou J, Somiari S, Lubert S, Saini J, Kane J, Deyarmin B, Hooke J, Mural R, Shriver C, Brinckerhoff C. Abstract P4-07-09: The Impact of Matrix Metalloproteinase-1 Promoter 1G/2G Polymorphism on Breast Diseases. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p4-07-09] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Matrix Metalloproteinase-1 (MMP-1) is a ubiquitously expressed interstitial collagenase. Overexpression of MMP-1 has a role in initiating mammary tumorigenesis by degrading stroma and by releasing growth factors. A single guanine insertion polymorphism in the MMP-1 promoter creates the binding site, 5'-GGAA-3', for the Ets transcription factor, and increases transcription of MMP-1. The MMP-1 2G polymorphism is linked to early onset, increased risk or aggressiveness of several cancers. Its relationship with other potential markers in invasion and metastasis of breast cancer is unknown.
Experimental Design: To study the impact of the 2G polymorphism on breast cancer we analyzed the genotypes of 109 patients (52 invasive breast cancer [IBC], 29 ductal carcinoma in situ [DCIS], 13 atypical ductal hyperplasia [ADH] and 15 benign breast disease). Immunohistochemical (IHC) data for MMP-1, HER2, ER/PR and P53 from these donors were also analyzed. IHC results for MMP-1 were scored as 0 (no expression) or increasing expression of+1, +2 or +3. Data were analyzed using Pearson's chi-square test to identify statistical significance.
Results: A significantly higher number of patients in the IBC group expressed high MMP-1 (+2 and +3; p <0.001) while the benign group had the least number of patients expressing higher MMP-1 (score +3; p = 0.0075). In the IBC group, among patients with low levels of MMP-1 (+1), 57% had the 1G/1G phenotype, and among those expressing high levels of MMP-1 (+2 and +3), over 70% were 1G/2G heterozygotes or 2G/2G homozygotes. The 2G allele frequency in the ADH group was 0.62 and these patients had higher MMP-1 expression (+2 and +3). Further analyses of HER2, ER/PR and P53 in relation to the MMP-1 polymorphism within the IBC group showed MMP-1 allelic variation in Her-2 positive group was significantly different compared with Her-2 negative group (p = 0.039), with a distribution curve shifted to a greater frequency of 2G homozygosity. A similar result was also observed in P53 positive group when compared with P53 negative group (p = 0.043).
Conclusions: 1) In the IBC group, the 2G insertion polymorphism contributes to MMP-1 over expression. 2) Increased expression of MMP-1 in ADH and higher 2G allele frequency are consistent with the hypothesis that increased MMP-1 2G polymorphism plays a role in initiation of ADH through up regulation of MMP-1 expression. 3) Earlier studies show prognostic role for the coexistence of increased expression of HER2 and P53 in breast cancer. Our observation of a significant increase in the 2G homozygotes in HER2 and P53 positive patients supports a prognostic role for this polymorphism and suggests its possible association with other breast cancer markers. Thus, the MMP-1 2G polymorphism may both contribute to breast disease onset and serve as a prognostic marker for breast cancer.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-07-09.
Collapse
Affiliation(s)
- J Zhou
- Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington DC; Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | - S Somiari
- Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington DC; Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | - S Lubert
- Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington DC; Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | - J Saini
- Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington DC; Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | - J Kane
- Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington DC; Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | - B Deyarmin
- Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington DC; Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | - J Hooke
- Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington DC; Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | - R Mural
- Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington DC; Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | - C Shriver
- Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington DC; Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | - C. Brinckerhoff
- Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington DC; Dartmouth-Hitchcock Medical Center, Lebanon, NH
| |
Collapse
|
2
|
Kvecher L, Wu W, Hooke J, Shriver C, Mural R, Hu H. An Approach To Correlate the Temporal Information To Facilitate Specimen Selection in the Breast Cancer Research Project. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-4173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Temporal information management is very important in translational research. In the Clinical Breast Care Project (CBCP), the information on subjects and their specimens may be collected at multiple time points using multiple instruments.All such information is stored in an in-house data warehouse. Currently, 4000+ subjects have been enrolled in the study following HIPAA-compliant IRB-approved protocols with 35,000+ specimens collected. Some of the patient's information is static but other data are time dependent. As a result, selecting samples for experiments is a challenge due to complicated temporal relationships between samples and information collected through various instruments.Methods and Results: In the CBCP, the clinical information, blood, and solid tissues of a subject may be collected at multiple time points, associated with the completion of a Core Questionnaire (CQ) for clinical information, and/or a Pathology Checklist (PC) for pathology and sample information. We have designed and implemented an algorithm to use a set of pre-defined flags to precisely describe each sample related to patient's clinical and pathology information in the temporal domain. Five categories (flags) were created to describe the relationship between the sample date (SD) and the CQ date based on whether SD is within 60 days of the CQ date or there is missing data or not. The relationship between blood samples and pathology information is more complicated. Within 90 days, any of the 15 surgical procedures might be performed on a patient and blood samples might be collected before, at the time of, or between any procedures. For some experiments, it is crucial to select blood samples taken before tumor is impacted or severely impacted. Thus, we defined a dozen categories to describe the relationship between the SD and the procedure date (PD), including when the SD is earlier than any PD, equals to the first PD, or between certain procedures. Using these flags we have characterized the relationships between SDs and CQ dates, and between SDs and PDs for all the samples and all the subjects, and stored all the information into two relational tables. The temporal criteria for sample selection are now represented by the relationships between these flags, and can be implemented through several filtering processes. The described algorithm drastically reduces the time needed for precise sample selection from several days for manual efforts to several hours.Discussion: We are in the process of developing a general data model for temporal information management. The method described here is a transitional solution that fulfills our current needs. As an initial effort some of the thresholds for categorizing different temporal conditions are arbitrary, and we are validating them with experimental results for future improvement. Nonetheless, this algorithm has greatly enhanced the efficiency of our subject and specimen selection for wet bench experiments. The same principle can be applied to the future temporal data model solution, for CBCP and other human disease studies.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4173.
Collapse
Affiliation(s)
| | - W. Wu
- 1Windber Research Institute, PA,
| | - J. Hooke
- 2Walter Reed Army Medical Center, DC,
| | | | - R. Mural
- 1Windber Research Institute, PA,
| | - H. Hu
- 1Windber Research Institute, PA,
| |
Collapse
|
3
|
Ellsworth R, Weyandt J, Fantacone-Campbell J, Deyarmin B, Ellsworth D, Hooke J, Shriver C. Genetic Characterization of Columnar Cellular Lesions and Atypical Ductal Hyperplasia of the Breast. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-5156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aims: Columnar cell lesions (CCL) and atypical ductal hyperplasia (ADH) frequently coexist and share molecular changes with in situ and invasive components, suggesting that CCL and ADH may be precursors to breast cancer. These conclusions are, however, largely based on studies examining CCL and/or ADH from patients diagnosed with more advanced disease. Thus, we assessed allelic imbalance (AI) in pure CCL or ADH specimens to characterize molecular changes in early breast lesions.Methods and results: DNA samples were obtained from laser microdissected lesions from CCL with (n=42) or with ADH (n=31) without concurrent in situ or invasive disease. AI was assessed at 26 chromosomal regions commonly altered in breast cancer. The average AI frequency was 6.2% (range 0-20%) in CCL and 6.1% (range 0-25%) in ADH with no significant difference in levels of AI between CCL and ADH. The highest levels of AI were on chromosomes 8q24 and 17q21 in ADH (23%) and CCL (15%), respectively.Conclusions: In conjunction with low overall levels of AI, chromosomal alterations that characterize low- and high-grade in situ and invasive disease were not frequent in pure CCL and ADH. Thus, pure lesions are not genetically advanced and are molecularly distinct from synchronous lesions.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5156.
Collapse
Affiliation(s)
| | | | | | | | | | - J. Hooke
- 3Walter Reed Army Medical Center, DC,
| | | |
Collapse
|
4
|
Shay M, Duman J, Eberly S, Christiansen R, Hu H, Shriver C. Converting Paper Medical Records to Electronic Version To Support Breast Cancer Translational Research and Clinical Practice. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-5123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The healthcare system has extremely large volumes of patients' paper medical records (PMRs) scattered throughout various medical facilities. Currently the industry is transitioning to Electronic Medical Records (EMR). Although each source of information is equally important, a complete longitudinal health record is rarely available or currently attainable. The goal of this effort is to convert the existing PMRs into searchable electronic equivalents and merge them with existing EMRs to create a more complete longitudinal health record to support clinical care and biomedical research.Method: Using a subset of PMRs for subjects enrolled in the Clinical Breast Care Project at Walter Reed Army Medical Center, (WRAMC), we are developing an automated method to digitize and index the records, extract the biomedical information and prepare the data for delivery to clinicians and researchers. The electronic records were loaded into a database for immediate access by clinicians. To support translational research, MRs need to be de-identified, and information extracted and loaded into a research database; we used ten MRs to develop the operational method. Several methods were tested in the de-identification process: 1) manually, by striking out the protected health information (PHI) on paper before it was digitized and 2) “electronically”, by redacting the record electronically on the computer after it was digitized. We are in the process of testing automated data extraction tools and natural language processors to automatically de-identify and extract data from the EMR.Result: We quickly realized that only 10% of PMRs existed onsite at WRAMC; remaining MRs were held by the patients or other medical facilities. Approximately 300 PMRs, containing 66,600 pages, were scanned and digitized for this project. We have created a successful digitization process, which includes creating PDFs with hidden and searchable information. We have compared the effort and accuracy of various redaction methods. To de-identify 10 records, it took ∼10 hours manually and ∼20 hours electronically. It took longer electronically because of the preparations to ensure the removed information could not be retrieved. We expect that automated redaction tools will greatly reduce that effort. We also found that the electronic method had a 99% accuracy compared to 96% for the paper method. A portal prototype to allow access to medical records by clinicians and researchers is currently being tested and evaluated.Discussion: Conversion of non-searchable data into an explorable and computable format will enable clinicians to acquire needed information more conveniently in their clinical care including treatment plan development. Similarly, properly de-identified, complete MRs will serve as a rich source of clinical information to support translational research. Although the method we are developing will initially satisfy the CBCP need for clinical service and research, it will be further developed into a full solution to expand into other disease condition fields.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5123.
Collapse
Affiliation(s)
- M. Shay
- 1Concurrent Technologies Corporation (CTC),
| | - J. Duman
- 2National Interest Security Company LLC (NISC),
| | - S. Eberly
- 2National Interest Security Company LLC (NISC),
| | | | - H. Hu
- 3Windber Research Institute,
| | | |
Collapse
|
5
|
Ellsworth R, Seeley E, Ellsworth D, Deyarmin B, Hooke J, Sanders M, Caprioli R, Shriver C. Proteomic Discrimination of Well- from Poorly-Differentiated Breast Carcinomas. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-6126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pathological grade is a useful prognostic factor for stratifying breast cancer patients into favorable (well-differentiated tumors) and less favorable (poorly-differentiated tumors) outcome groups. The current system of tumor grading, however, is highly subjective and a large proportion of tumors are characterized as intermediate-grade, making determination of optimal treatments difficult.Methods: Primary breast tumor specimens from patients diagnosed with well- (n=27) and poorly-differentiated (n=51) invasive ductal carcinoma were obtained from patients enrolled in the Clinical Breast Care Project. Frozen tissues were sectioned and mounted on gold coated MALDI target plates for protein expression profiling. Hematoxylin and eosin (H&E) stained slides were prepared from serial sections for histological characterization. MALDI matrix was deposited as individual spots on the tissue sections in a histology directed manner to assay specific areas and tissue types of interest. Mass spectral data were then acquired from multiple sites across each tissue section.Results: 129 features were observed in well-differentiated and 132 in poorly-differentiated tumors. While the majority of features detected were similar between the two groups, 6 protein features were expressed at significantly lower and 12 at significantly higher levels in the poorly-differentiated tumors, including increased expression of Calgranulin A and Calgizzarin.Conclusions: Protein expression differences detected here suggest that well- and poorly-differentiated invasive breast tumors are molecularly distinct diseases and that these protein changes may contribute to the structural integrity of the tumor cell. In particular, calgranulin A and calgizzarin are members of the S100 protein family, and function in processes such as cell proliferation and differentiation. Further refinement of this differentiation protein signature may not only improve our understanding of the biological processes involved with tumor grade but provide pathologists with new molecular tools to classify breast tumors and reduce the subjectivity associated with current grading criteria.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6126.
Collapse
Affiliation(s)
- R. Ellsworth
- 1Henry M. Jackson Foundation for the Advancement of Military Medicine, PA,
| | - E. Seeley
- 2Vanderbilt University Medical Center, TN,
| | | | | | - J. Hooke
- 4Walter Reed Army Medical Center, DC,
| | - M. Sanders
- 2Vanderbilt University Medical Center, TN,
| | | | | |
Collapse
|
6
|
Iida J, Nesbella M, Lehman J, Mural R, Shriver C. Role for CD44 in Enhancing Invasion, Migration, and Growth of Triple Negative (TN) Breast Cancer Cells. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-6161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple negative (TN) breast cancers are defined by a lack of expression of estrogen, progesterone, and her-2/neu receptors. It is widely recognized that TN breast cancers have a poorer prognosis than any other subtypes of breast caner. Given the lack of effective targeted therapies for TN breast cancer patients, understanding of the mechanisms of growth and invasion in the tissues provides insight into developing novel approaches to lower the mortality from TN breast cancer.Neoplastic epithelial cells in breast carcinomas interact with various components in the tissue microenvironment including extracellular matrix (ECM) and mesenchymal cells. Recent studies identified CD44 as a metastasis-related molecule with multiple functions by promoting cell-cell and cell-ECM interactions. CD44 is an integral transmembrane protein encoded by a single 20-exon gene. In the standard form (CD44s), 10 of the 20 exons are translated. Multiple variant isoforms exist (CD44v1-10) which arises from alternate mRNA splicing of the remaining 10 exons. In contrast to the ubiquitous expression of the standard form of CD44, splice variants are highly restricted in their expression in normal or malignant tissues. Indeed, CD44 variants containing v3, v5, v6, v7-8, v10 exons are expressed in malignant breast cancer tissues. However, there is limited information regarding the biological functions of these exons to promote tumor invasion and metastasis. The goal of this study is to evaluate specific exon(s) of CD44 expressed on TN breast cancer cells for promoting tumor progression and metastasis.In order to approach this goal, we utilized three TN cell lines (HCC38, HCC1937, and HCC1806) as model systems to evaluate CD44 in regulating invasion, migration, and growth in extracellular matrix (ECM) environments. Reverse transcriptase (RT)-PCR analysis using exon specific primers indicate that these cells expressed CD44v8-v10 and CD44s. We demonstrated that an inhibitory antibody against exon v10 of CD44 significantly inhibited b1 integrin-mediated migration and invasion into Matrigel and type I collagen gel. Importantly, this antibody also inhibited three dimensional (3D) growth which is a b1 integrin-independent process. The significant inhibition of these processes was also achieved when a FLAG-fusion exon v10 peptide (FLAG-v10, in which FLAG is tagged at the N-terminal of the peptide) was used as an inhibitor, implying that this exon would function to assemble molecular complexes on TN breast cancer cells that facilitate invasion, migration, and growth. Thus, these results suggest that generation of small synthetic molecules that block the functions of exon v10 of CD44 is promising approaches to inhibit invasion and metastasis of TN breast cancer cells.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6161.
Collapse
Affiliation(s)
- J. Iida
- 1Windber Research Institute, PA,
| | | | | | - R. Mural
- 1Windber Research Institute, PA,
| | | |
Collapse
|
7
|
Li X, Hu H, Shriver C, Mural R. Microarray Data Analysis Using Peripheral Blood Samples Suggests Differential Enrichment of Signaling Pathways between Breast Cancer Patients and Normal Subjects. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer is the second most common cancer among women in the United States and the second leading cause of cancer death in women. Early and accurate diagnosis is crucial for better treatment and reduction of mortality. Diagnostics based on blood samples are being developed for many diseases including a variety of cancers.Gene expression profiling has been widely used to investigate the mechanisms of tumorigenesis with the goal of developing novel treatment strategies. We have applied microarray technology to study the gene expression signatures in blood samples from patients with invasive breast cancer, with benign breast disease and from disease free (normal) control groups to find potential diagnostic patterns. We have identified differentially expressed genes in each group and investigated the pathways these genes are involved in and how these are regulated.Material and Methods: Human blood samples from 102 invasive breast cancer patients, 57 patients with benign breast disease and 102 normal controls were collected for this study. Patients are enrolled in the Clinical Breast Care Project (CBCP) following HIPAA-compliant IRB approved protocols, with proven breast pathology diagnosis categories. Affymetrix HG-U133 Plus 2 GeneChips were used to investigate the gene expression profile. Microarray experiments were performed following Affymetrix protocols. CEL files were then analyzed with RMA algorithm for the calculation of gene expression matrix. Differentially expressed genes were identified between different groups using Wilcoxon rank sum test. We also applied Gene Set Enrichment Analysis (GSEA) to the entire gene expression profiles to investigate the gene sets or pathways enriched in different groups.Results: We identified about 2,051 differentially expressed genes between normal and invasive groups (p < 0.001 and Fold Change > 1.2). Furthermore, about 445 and 51 genes were identified in normal vs. benign and benign vs. invasive groups respectively. We performed GSEA using 395 gene sets from pathway databases, initially focusing on normal vs. invasive groups. 123 gene sets are highly expressed in the normal group and 272 gene sets are highly expressed in the invasive group. For the normal group, 10 gene sets are significantly enriched and 22 gene sets are significantly enriched in the invasive group (p < 0.05). These results show that some important pathways are down regulated in the invasive group, such as, the B-cell antigen receptor pathway, the BCR signaling pathway, the T-cell signal transduction pathway, the IL4 receptor pathway, the PIP3 pathway, the ERK pathway, etc. The pathways up regulated in the invasive group are oxidative phosphorylation pathway, ATP synthesis, etc.Discussion: Our results suggest that a list of genes differentially expressed in different groups and they may be used to compose cancer marker panels which can be integrated with currently clinical procedures for cancer diagnosis. We also find some crucial pathways enriched in each group. Most of the pathways downregulated in the blood of patients in the invasive group are related to the immune response. In contrast, most of pathways upregulated in the blood of patients in the invasive group are associated with metabolism.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3024.
Collapse
Affiliation(s)
- X. Li
- 1Windber Research Institute,
| | - H. Hu
- 1Windber Research Institute,
| | | | | |
Collapse
|
8
|
Bekash A, Saini J, Fan X, Hooke J, Mural R, Shriver C, Hu H. Differential Benign Breast Disease Co-Occurrence with Cancer in Caucasian and African American Women. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3066] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast Cancers (BCs) in Caucasian (CA) and African American (AA) women have different characteristics. Recently, there have been reports, mostly focusing on Caucasians that Benign Breast Diseases (BBDs) may be risk factors for BCs. There are also a few reports of different co-occurring patterns of BBDs with BCs between the two populations. In the Clinical Breast Care Project (CBCP) more than 4,000 subjects have been enrolled following HIPAA-compliant, IRB-approved protocols, with more than 35,000 biospecimens collected. For patients requiring biopsies, an expanded pathology report for research is completed. The occurrences of any of the 131 pathologic conditions, including 66 BBDs, are recorded. All the results are reviewed by the same pathologist. The CBCP provides a uniformed pathology dataset for a comprehensive characterization of the association of BBDs with BCs.Method: The diagnoses were made from potentially multiple biopsies obtained over a short period of time, mostly within 60 days. CBCP subjects with BBD diagnosis and ethnicity information from their most recent visit were selected, giving a dataset totaling 1479 CA and 484 AA women. We studied the association between BBDs and BCs (including in situ, invasive, and malignant NOS) in these two groups using the chi-square test.Results: In both populations 6 BBDs are positively associated with BCs, including atypical ductal hyperplasia (ADH) (4% vs 15% for AA p<3.8E-05, meaning 4% cancer-free cases with ADH compared to 15% cancer cases co-occurring with it; 7% vs 16% for CA p<1.9E-08), microcalcifications (27% vs 56% for AA p<1.2E-09, 35% vs 53% for CA p<8.0E-12), multiple (peripheral) papillomas (6% vs 16% for AA p<0.0005, 4% vs 8% for CA p<0.0002), columnar cell hyperplasia (9% vs 21% for AA p<0.0003, 6% vs 18% for CA p<3.5E-12), and moderate intraductal hyperplasia (IDH) (14% vs 28% for AA p<0.0002, 14% vs 18% for CA p<0.03). On the contrary, 3 BBDs are negatively associated with BCs including fibroadenoma (30% vs 10% for AA p<4.9E-07; 21% vs 7% for CA p<1.0E-13), and mild IDH (10% vs 2% for AA p<0.003; 13% vs 7% for CA p<0.0002). Eight BBDs differentially co-occur with BCs between AA and CA. BCs in AA are associated with sclerosing adenosis (13% vs 31%, p<4.5E-06), fibrocystic changes (45% vs 61%, p<0.001), fibroadenomatoid nodule (6% vs 12%, p<0.042), and cysts (42% vs 57%, p<0.004). BCs in CA are positively associated with columnar cell hyperplasia with atypia (3% vs 8% p<3.6E-05), atypical lobular hyperplasia (1% vs 5%, p<6.0E-05), and radiation changes (0% vs 1.4% p<0.004), but negatively associated with duct ectasia (10% vs 2%, p<7.9E-10).Discussion Our findings are in accordance with established BC risk factors such as ADH and moderate IDH for both ethnic groups. We further found that 8 BBDs differentially co-occur with BCs between AA and CA groups, and interestingly the 4 significant BBDs detected in the AA group typically show >10% increased co-occurrence rate in cancer cases compared to cancer-free cases, whereas the 4 BBDs detected in the CA group almost always show a <10% co-occurrence rate overall. More research is undergoing to understand the implications of this distinct co-occurrence pattern.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3066.
Collapse
Affiliation(s)
| | - J. Saini
- 1Windber Research Institute, PA,
| | - X. Fan
- 1Windber Research Institute, PA,
| | - J. Hooke
- 2Walter Reed Army Medical Center, DC,
| | - R. Mural
- 1Windber Research Institute, PA,
| | | | - H. Hu
- 1Windber Research Institute, PA,
| |
Collapse
|
9
|
Mittendorf E, Hueman M, Storrer C, Shriver C, Ponnaiah S, Peoples G. Evaluation of the Cd107a cytotoxicity assay for the detection of cytolytic CD8 cells recognizing Her2/neu vaccine peptides. J Surg Res 2004. [DOI: 10.1016/j.jss.2004.07.194] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Abstract
Carotid body tumors (CBTs) have an unpredictable history with no correlation between histology and clinical behavior. Of reported cases since 1891, local and distant metastases appear in approximately 10% of cases and remain the hallmark of malignancy. Currently, there are not enough data to support a single treatment regimen for malignant CBTs. The reported case demonstrates some unanswered issues with regard to malignant CBTs to include lymph node dissection, the need for carotid resection, and the role of radiation therapy. A 46-year-old pathologist underwent a resection of a Shamblin I CBT, to include jugular lymph node sampling, without complication. There was lymph node involvement, and tumor cells were found on the margins of the pathologic specimen. Subsequent carotid resection with reversed interposition saphenous vein graft and modified neck dissection were performed again without complication. Follow-up at 4 years has been uneventful. Diagnosis of CBTs with the use of magnetic resonance angiography, magnetic resonance imaging, color flow duplex scanning, and the role of arteriography are reviewed. The current treatment options are discussed with reference to primary lymph node sampling, carotid resection, and neck dissection in malignant cases. This case demonstrates that the unpredictable nature of CBTs and their malignant potential warrant aggressive initial local treatment to include jugular lymph node sampling and complete tumor resection.
Collapse
Affiliation(s)
- A Dias Da Silva
- Vascular Surgery Service, Hospital Geral de Santo António and D. Pedro V Military Hospital, Porto, Portugal.
| | | | | | | | | | | |
Collapse
|
11
|
Grobmyer SR, Guillem JG, O'Riordain DS, Woodruff JM, Shriver C, Brennan MF. Colonic manifestations of multiple endocrine neoplasia type 2B: report of four cases. Dis Colon Rectum 1999; 42:1216-9. [PMID: 10496565 DOI: 10.1007/bf02238578] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Multiple endocrine neoplasia type 2B is best known for its endocrine manifestations and typical phenotype. The gastrointestinal manifestations, however, are also an important and commonly unrecognized component of the syndrome. We present four cases that demonstrate the varied presentation of patients with colonic manifestations of multiple endocrine neoplasia type 2B. We discuss the cause, diagnostic significance, and management of the colonic disease that is a component of multiple endocrine neoplasia type 2B.
Collapse
Affiliation(s)
- S R Grobmyer
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
| | | | | | | | | | | |
Collapse
|
12
|
Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, Feldman S, Kusminsky R, Gadd M, Kuhn J, Harlow S, Beitsch P. The sentinel node in breast cancer--a multicenter validation study. N Engl J Med 1998; 339:941-6. [PMID: 9753708 DOI: 10.1056/nejm199810013391401] [Citation(s) in RCA: 1414] [Impact Index Per Article: 54.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Pilot studies indicate that probe-guided resection of radioactive sentinel nodes (the first nodes that receive drainage from tumors) can identify regional metastases in patients with breast cancer. To confirm this finding, we conducted a multicenter study of the method as used by 11 surgeons in a variety of practice settings. METHODS We enrolled 443 patients with breast cancer. The technique involved the injection of 4 ml of technetium-99m sulfur colloid (1 mCi [37 MBq]) into the breast around the tumor or biopsy cavity. "Hot spots" representing underlying sentinel nodes were identified with a gamma probe. Sentinel nodes subjacent to hot spots were removed. All patients underwent a complete axillary lymphadenectomy. RESULTS The overall rate of identification of hot spots was 93 percent (in 413 of 443 patients). The pathological status of the sentinel nodes was compared with that of the remaining axillary nodes. The accuracy of the sentinel nodes with respect to the positive or negative status of the axillary nodes was 97 percent (392 of 405); the specificity of the method was 100 percent, the positive predictive value was 100 percent, the negative predictive value was 96 percent (291 of 304), and the sensitivity was 89 percent (101 of 114). The sentinel nodes were outside the axilla in 8 percent of cases and outside of level 1 nodes in 11 percent of cases. Three percent of positive sentinel nodes were in nonaxillary locations. CONCLUSIONS Biopsy of sentinel nodes can predict the presence or absence of axillary-node metastases in patients with breast cancer. However, the procedure can be technically challenging, and the success rate varies according to the surgeon and the characteristics of the patient.
Collapse
Affiliation(s)
- D Krag
- Cancer Center, Department of Surgery, University of Vermont, Burlington 05405, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
This article discusses the necessity of developing reliable and valid instruments to enhance case finding efforts among older adults who may be at risk for alterations in their optimal level of functioning and health. Case studies are provided to demonstrate to nurses how misconceptions can occur when assessment tools are neither reliable nor valid in extracting critical information. While the use of reliable and valid case-finding instruments can detect high-risk circumstances and reduce the likelihood of premature death and disability, erroneous information can have adverse economic and health consequences for the individual, family, and community.
Collapse
Affiliation(s)
- G A Bechtel
- Department of Community Nursing, Medical College of Georgia, USA
| | | |
Collapse
|
14
|
Cunningham JD, Fong Y, Shriver C, Melendez J, Marx WL, Blumgart LH. One hundred consecutive hepatic resections. Blood loss, transfusion, and operative technique. Arch Surg 1994; 129:1050-6. [PMID: 7944934 DOI: 10.1001/archsurg.1994.01420340064011] [Citation(s) in RCA: 203] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
BACKGROUND Hepatic resection is prone to significant blood loss. Adverse effects of blood loss and transfusion mandate improvements in surgical techniques to reduce blood loss and transfusion requirements. METHODS One hundred hepatic resections were carried out using a standard surgical technique that includes control of the hilar structures, extrahepatic control of the hepatic veins, and use of the Pringle maneuver. Low central venous pressure and Trendelenburg positioning were used during parenchymal transection. Data were collected retrospectively in the first 36 patients, whereas data were collected prospectively in the remaining 64 patients. RESULTS Hospital mortality was 3%. Median blood loss was 450, 700, 1000, 1100, and 1500 mL for segmental, nonanatomic, lobar, extended right, and extended left resections, respectively. Major resections were more likely than minor resections to be transfused with albumin (P = .008), fresh frozen plasma (P = .009), and packed red blood cells or whole blood (P = .04). Overall transfusion of packed red blood cells or whole blood occurred in 59 of 100 patients. In the 64 patients who were followed up prospectively, the predeposit of autologous blood decreased the need for homologous transfusions from 56% to 38%. A further reduction in the transfusion rate of 25% could have been possible if all patients in the prospective group had donated 2 U of autologous blood. Patients who predeposited blood were more likely to receive transfusions and to have had a transfusion more than 24 hours after surgery than were patients who did not donate blood. CONCLUSIONS The surgical techniques used results in acceptable blood loss and transfusion requirements for hepatic resection. This approach is safe, cost-effective, reproducible, and applicable for widespread use.
Collapse
Affiliation(s)
- J D Cunningham
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | | | | | | | | |
Collapse
|
15
|
Affiliation(s)
- P Collins
- Georgia Southern University, Statesboro 30460-8158
| | | | | |
Collapse
|